Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo do Mundo Real de Foslevodopa/Foscarbidopa para Avaliar Resultados de Qualidade de Vida em Participantes Adultos Mais Precocemente na Doença de Parkinson Avançada (PUCCINI)

6 de novembro de 2026 atualizado por: AbbVie

Um Estudo Global de Evidência do Mundo Real sobre a Eficácia e Segurança/Tolerabilidade de Foslevodopa/Foscarbidopa em Doentes numa Fase Mais Inicial da Doença de Parkinson Avançada

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.

There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being

Visão geral do estudo

Status

Recrutamento

Condições

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Ontario
      • Toronto, Ontario, Canadá, M5T 2S8
        • Recrutamento
        • Toronto Western Hospital /ID# 278384
    • Quebec
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Recrutamento
        • CIUSSS de l Estrie - CHUS /ID# 278379
    • City of Zagreb
      • Grad Zagreb, City of Zagreb, Croácia, 10000
        • Recrutamento
        • Klinicka Bolnica Dubrava /ID# 278408
    • Primorje-Gorski Kotar County
      • Rijeka, Primorje-Gorski Kotar County, Croácia, 51000
        • Recrutamento
        • Klinicki Bolnicki Centar Rijeka /ID# 278277
    • Barcelona
      • Sant Joan Despí, Barcelona, Espanha, 08970
        • Recrutamento
        • Hospital de Sant Joan Despi Moises Broggi /ID# 276895
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Recrutamento
        • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190
      • Tampa, Florida, Estados Unidos, 33613
        • Recrutamento
        • University of South Florida- Neuroscience Institute /ID# 278562
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28207-1196
        • Recrutamento
        • Novant Health /ID# 278567
    • Texas
      • Georgetown, Texas, Estados Unidos, 78628
        • Recrutamento
        • Texas Movement Disorder Specialists /ID# 278565
      • Jerusalem, Israel, 91120
        • Recrutamento
        • Hadassah Medical Center-Hebrew University /ID# 276211
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 91031
        • Recrutamento
        • Shaare Zedek Medical Center /ID# 276209
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Recrutamento
        • The Chaim Sheba Medical Center /ID# 276210
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Recrutamento
        • Tel Aviv Sourasky Medical Center /ID# 276212
      • Kanagawa, Japão, 231-0063
        • Recrutamento
        • Noge General Medicine and Neurology /ID# 280741
      • Tokushima, Japão, 770-0852
        • Recrutamento
        • Itsuki Hospital /ID# 280743
      • Tokyo, Japão, 202-0004
        • Recrutamento
        • Miwa Internal Medicine Clinic /ID# 280740
    • Saitama
      • Iruma-gun, Saitama, Japão, 3500495
        • Recrutamento
        • Saitama Medical University Hospital /ID# 280624
    • Tokyo
      • Bunkyo-ku, Tokyo, Japão, 113-8431
        • Recrutamento
        • Juntendo University Hospital /ID# 280623
      • Guaynabo, Porto Rico, 00969
        • Recrutamento
        • Centro Internacional De Mercadeo /ID# 276088
      • Newcastle upon Tyne, Reino Unido, NE3 3HD
        • Recrutamento
        • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752
    • Devon
      • Plymouth, Devon, Reino Unido, PL6 8DH
        • Recrutamento
        • University Hospitals Plymouth NHS Trust /ID# 284977
    • Hammersmith and Fulham
      • London, Hammersmith and Fulham, Reino Unido, W6 8RF
        • Recrutamento
        • Charing Cross Hospital /ID# 284211
      • Brasov, Romênia, 500326
        • Recrutamento
        • Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499
    • Bucharest
      • Bucharest, Bucharest, Romênia, 022328
        • Recrutamento
        • Fundeni Clinical Institute /ID# 277490
    • Iaşi
      • Iași, Iaşi, Romênia, 700620
        • Recrutamento
        • Arcadia Spitale Si Centre Medicale /Id# 277525
    • Timiș County
      • Timișoara, Timiș County, Romênia, 300724
        • Recrutamento
        • Neurotim Med /ID# 277500

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 69 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.

Descrição

Inclusion Criteria:

  • Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
  • A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
  • Adult male or female between 18 and 69 years of age
  • Disease duration (time since diagnosis) <10 years
  • Time since motor fluctuations started ≤5 years
  • H&Y Stage <3 in best "on"
  • "off" time of ≤ 4.5 hours per day
  • Naïve to LDp/CDp
  • Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
  • Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
  • Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
  • Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered

Exclusion Criteria:

  • History of any condition included in the contraindications section of the approved local Foslevodopa/Foscarbidopa (LDp/CDp) label in the participating country
  • History of treatment with any Device-Aided Therapy (DAT), such as Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa/Carbidopa Intestinal Gel (LCIG)/ Carbidopa/Levodopa Enteral Suspension (CLES), Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG)
  • Mini-Mental State Examination (MMSE) score <24
  • Participation in a concurrent investigational or observational clinical trial
  • Lack of motivation/insufficient language skills to complete the study questionnaires
  • History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis). In case of temporary affections like recent sunburn or open wounds, or in case of permanent affections like acne, scar tissue, tattoo, branding, or colorations, the participant should not be included if the Investigator considers these as interfering with infusion of study drug or study assessments.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Foslevodopa/Foscarbidopa

Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore
Prazo: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores
Prazo: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score
Prazo: Up to approximately 6 months

The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score
Prazo: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Prazo: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)
Prazo: Up to approximately 6 months

The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening.

Up to approximately 6 months
Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Prazo: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
Prazo: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.
Prazo: Up to approximately 6 months

The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.
Prazo: Up to approximately 6 months

Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe.

Up to approximately 6 months
Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire
Prazo: Up to approximately 6 months

The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.
Prazo: Up to approximately 6 months

The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse.

Up to approximately 6 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.
Prazo: Up to approximately 6 months

Measured by dedicated questionnaire.

Up to approximately 6 months
Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12
Prazo: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale
Prazo: Up to approximately 6 months

The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy).

Up to approximately 6 months
Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)
Prazo: Up to approximately 6 months

Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident.

Up to approximately 6 months
Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale
Prazo: Up to approximately 6 months

The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living.

Up to approximately 6 months
Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)
Prazo: Up to approximately 6 months

Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options.

Up to approximately 6 months
Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Prazo: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Healthcare Resource Utilization (HRU)
Prazo: Up to approximately 6 months

Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists.

Up to approximately 6 months
Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)
Prazo: Up to approximately 6 months

Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6

Up to approximately 6 months
Questionnaire to investigate the practicalities of the infusion system
Prazo: Up to approximately 6 months

Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments).

Up to approximately 6 months
Number of Participants with Adverse Events (AEs)
Prazo: Up to approximately 6 months

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: ABBVIE INC., AbbVie

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de agosto de 2026

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

1 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2025

Primeira postagem (Real)

13 de novembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever